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Abstract
Background: The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine)
amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of
the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and
therapy monitoring.
Methods: Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass
spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from
administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman
correlation analysis.
Results: We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats.
Similar results were observed in randomly selected patients involved in Phase I clinical trials.
Conclusions: RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin. Since
retinol metabolism is disrupted in many cancers and inversely associates with malignancy, these data identify a
potential novel mechanism for the action of LA-12 and other similar anti-cancer drugs.
Keywords: (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12), plasma retinol-binding
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Background
The platinum-based anti-cancer drug, cisplatin (cis-dia-
mminedichloroplatinum(II)), is commonly used for
treatment of various types of carcinomas, including
breast, testicular, ovarian, head and neck or lung cancer
[1], with significant anti-tumor activity. However, its
clinical use is substantially complicated by numerous
side effects such as nephrotoxicity, neurotoxicity and
nausea as well as by intrinsic or acquired resistances.
Significant efforts were therefore dedicated to develop
novel platinum-based complexes to reduce the side
effects of cisplatin, to overcome platinum resistance and
to introduce novel mechanisms of anti-cancer action.
Two derivatives, carboplatin (cis-diammine-(1,1-cyclobu-
tanedicarboxylato)platinum(II)) and oxaliplatin (trans-[R,
R-cyclohexane-1,2-diammine]oxalatoplatinum(II)), have
been approved by the Food and Drug Administration
for clinical use [2,3]. The requirement for their intrave-
nous administration, in addition to substantial side
effects, led to the development of a new generation of
platinum-based drugs such as satraplatin ((OC-6-43)-bis
(acetato)amminedichloro(cyclohexylamine)platinum(IV)),
known also as JM216, the first orally administered plati-
num compound evaluated in clinical trials [2,4,5]. We
studied the biological properties of an alternative plati-
num(IV) complex called LA-12, (OC-6-43)-bis(acetato)
(1-adamantylamine)amminedichloroplatinum(IV), con-
taining 1-adamantylamine instead of cyclohexylamine
non-leaving ligand [6] which provides different chemical
and biological properties and which has also entered
into clinical evaluation. LA-12 has shown a higher cyto-
toxicity than satraplatin when tested on a panel of 14
cancer cell lines of various origins and different cisplatin
sensitivities [6,7] and no cross-resistance with cisplatin
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[6,8]. LA-12 has also shown higher anti-tumor activity
in comparison with cisplatin and satraplatin, favorable
pharmacokinetics and relatively low acute toxicity in a
panel of pre-clinical in vivo studies [9-11]. Generally,
the cytotoxic mode of cisplatin action is mediated by its
interaction with DNA to form DNA adducts, primarily
intra-strand crosslink adducts, which activate several sig-
nal transduction pathways, including those involving
ATR, p53, p73 and MAPK, and culminate in the induc-
tion of apoptosis [12]. The mechanisms of LA-12 action
are not fully understood. There is evidence that expo-
sure to LA-12 can disrupt cell proliferation and induce
apoptosis more potently than cisplatin in both p53
dependent and independent manners [13,14]. In particu-
lar, LA-12 induces unique changes in the profile of gene
expression compared to cisplatin, indicating a distinct
mode of action resulting in the differential activation of
both p53-dependent and p53-independent gene targets
[15]. Most recently, LA-12 has been shown to have a
greater inhibitory effect than cisplatin on heat shock
protein 90 function [16].
To understand the molecular mechanisms of LA-12
action and identify serum markers for LA-12 activity in
cancer patients, we performed dose-response and time-
course studies using mass-spectrometry-based analysis
to measure the proteomic profiles of rat plasma in
response to LA-12 and compared them with the recent
pharmacokinetic data [17]. Such an experimental design
enables identification of LA-12 target proteins which
could potentially serve as markers of LA-12 treatment,
response and therapy monitoring. Using the surface-
enhanced laser desorption-ionization time-of-flight mass
spectrometry (SELDI-TOF MS) approach [18] we identi-
fied Retinol-binding protein 4 (RBP4) as significantly
correlating with LA-12 level in both rat plasma and rat
plasma ultrafiltrate and in the plasma of patients under-
going LA-12 treatment in Phase I clinical trials. In view
of the known roles of retinol in controlling cellular dif-
ferentiation and the abnormal expression of RBP4 in
cancer [19], these data contribute to understanding LA-
12 action as an anti-cancer agent and identify RBP4 as a
serum marker for LA-12 activity.
Methods
Chemicals, animals and dosing
LA-12 was synthesized by Pliva-Lachema. 36 male
albino Wistar-Hahn rats (6-8 weeks of age, 235-268 g)
were kept under 12-h light/dark cycle with free access
to water and standard diet for 13 days for acclimatiza-
tion prior to experiments. All animal protocols were
approved by the Institute’s Animal Experimental Ethics
Committee and animals were treated according to
OECD guidelines. In the morning after overnight fast-
ing, LA-12 was administered by a gastric gavage in a
volume of 1 mL/kg of body weight as suspension in a
0.6% water solution of methylcellulose. Rats were ran-
domly assigned to four LA-12 dosing groups of 9 rats
dosed with 37.5 - 75 - 150 - and 300 mg LA-12/kg body
weight each and, furthermore, to two of six blood sam-
pling intervals (pre-dose and at 2, 8, 24, 48 and 72 h
after dosage). Each combination of dosage and blood
sampling time was thus represented by three animals.
Two blood samples of 2 mL each were taken (at differ-
ent times after dosage) from retro-orbital plexus under
ether anesthesia. Blood was collected into polypropylene
test tubes containing 0.75% K3EDTA (20 μL/mL of
blood) and cooled in water bath (8°C) for 5 min. The
samples were then centrifuged at 3000 g and 8°C for 10
min. The first aliquot (0.1 mL) of the supernatant was
immediately frozen at -18°C while plasma ultrafiltrate
was prepared from the remaining blood volume (see
[17] for protocol) and stored at -18°C. After the second
blood sampling interval, rats were killed by withdrawing
whole blood from the abdominal artery.
SELDI-TOF MS analysis
20 μL of rat plasma were denatured with 30 μL of sam-
ple solution (9 M urea, 2% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS)) for 30
min at room temperature (RT). Denatured plasma pro-
teins were centrifuged (10,000 ×g/20 min/RT), the
supernatant was mixed with 90 μL of IMAC binding
buffer (Bio-Rad, USA) and loaded on IMAC-Cu SELDI
chips according to manufacturer’s instructions. After
matrix (sinapinic acid) application, sample protein com-
position was analyzed using SELDI-TOF MS in PBS IIc
Protein Chip Reader (Bio-Rad, USA) as described pre-
viously [18,20]. All samples characterized by one of four
LA-12 doses and one of six time intervals, each obtained
by three independent blood collections from individual
animals (biological replicates) were measured twice;
4*6*3*2 = 144 averaged MS spectra were thus obtained.
Peak clustering was performed with Biomarker Wizard
software (Bio-Rad, USA) with signal/noise (S/N) > 5 and
5% minimum spectra detection in the first pass and
then peaks with S/N > 3 in cluster mass window of
range 0.3% were added; the valley depth was set to three
fold of noise. Intensities of corresponding peaks across
all six replicates (three biological replicates, each mea-
sured twice) were then averaged before quantitative sta-
tistical analysis.
Platinum concentration measurement
Platinum concentration in both rat plasma and ultrafil-
trate samples as well as in human plasma samples were
determined by a validated method based on electrother-
mal atomic absorption analysis with Zeeman back-
ground correction, as described previously [17]. An
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AAnalyst 800 spectrometer (Perkin Elmer, Norwalk, CT,
USA) with longitudinal AC-Zeeman-effect background
correction with transversely heated graphite tube
(THGA™) and autosampler AS 800 were used [17].
Statistical analysis
The primary SELDI-TOF MS data consisting of six
replicates (three biological replicates, each measured
twice) were inspected for outliers and aggregated using
average prior further statistical analyses. Values under
detection limit were taken as half of this limit. Standard
nonparametric descriptive statistics were adopted, i.e.
median and percentile range.
The platinum concentrations in response to LA-12
dose and time since drug administration were statisti-
cally evaluated using Kruskal-Wallis test. The average
intensities of all 92 protein peak clusters across the
whole SELDI-TOF MS experiment were correlated with
platinum concentration in corresponding samples using
Spearman rank correlation coefficient. All analyses were
performed using Statistica 9 software (StatSoft, Inc.,
USA).
Protein identification
For identification of proteins that correlate with plasma
platinum level, rat plasma samples containing highest
levels of the proteins of interest were pre-separated
using four IMAC Spin Columns (Bio-Rad, USA) (1 mg
of total protein for each column) according to the man-
ufacturer’s instructions, with 2 × 100 μL of 250 mM
imidazole in binding buffer as the elution buffer. Eluted
protein mixtures were dialyzed overnight against 40 mM
Tris-HCl buffer (pH 7.0), combined and dried under
vacuum. The pellet of IMAC pre-separated proteins was
resolubilized in 80 μL of sample solution containing
10% acetonitrile and 0.1% trifluoroacetic acid for further
reverse phase-liquid chromatography fractionation. This
fractionation was performed on an Agilent HP 1100
HPLC system (Agilent Technologies, Santa Clara, CA,
USA) using a Discovery Bio Wide Pore C18 column (10
cm × 2.1 mm, 5 μm particle size; Sigma-Aldrich Corp.,
St. Louis, MO, USA) with a 2 cm guard precolumn.
Separations were performed at 35°C, mobile phase A
consisted of 0.1% trifluoroacetic acid in water while
mobile phase B consisted of 0.1% trifluoroacetic acid in
acetonitrile. The proteins were eluted using a linear gra-
dient of mobile phase B (0% to 91% B in 15 min, then
91% B to 96% B in 18 min, then 96% B to 100% B in 2
min) followed by elution using 100% mobile phase B in
10 min; the flow rate was 100 μL/min (following the
method of Moshkovskii et al. [21], with several modifi-
cations). Sixty collected fractions (60 μL each) were
dried under vacuum and resolubilized in 20 μL 10%
acetonitrile and 0.1% trifluoroacetic acid for protein
profile determination on SELDI-TOF MS (2 μL of each
resolubilized fraction was analyzed on NP-20 chips).
The proteins were redissolved in 20 μL of sample buffer
(consisting of 12% SDS, 6% mercaptoethanol, 30% gly-
cerol, 0.05% Coomassie Brilliant Blue G-250 and 150
mM Tris-HCl, pH 7.0), heated (95°C/3 min), centrifuged
(16,000 × g/20 min/4°C) and separated using tricine
SDS-PAGE on PROTEAN II XL apparatus (Bio-Rad,
USA) according to Schägger [22]. The gel - consisting
of 4% sample loading gel, 10% spacer gel and 16%
separation gel - was stained using colloidal Commassie
Blue [23]. The bands with appropriate molecular weight
were cut out and digested by trypsin as described pre-
viously [24]. Mass spectra were recorded in positive
reflectron mode on a 4800 MALDI TOF/TOF™ mass
spectrometer (Applied Biosystems, Framingham, MA,
USA) equipped with an Nd:YAG laser (335 nm) using
3-7 ns pulse and with 200-Hz firing rate. Delayed
extraction was used in all experiments being optimized
for m/z = 2100 in MS mode. The maximum pulse
energy was 23 μJ, it was attenuated appropriately for
sample analysis. Accelerating voltage of the ion source
was set to 20 kV in the MS mode. In the MS/MS mode,
the accelerating voltage was 8 kV; it was modified after
ion selection so the ions passing the collision cell pos-
sessed 1 keV of kinetic energy; the accelerating voltage
rose to 15 kV after ions passed the collision cell. Dual
microchannel plate detector voltage was set to 1.86 kV
in MS mode and 2.10 kV in MS/MS mode. MS spectra
were acquired in the mass range of 800-4000 m/z and
calibrated internally using the monoisotopic [M+H]+
ions of trypsin autoproteolytic fragments (842.509 Da
and 2211.104 Da). Peak detection was performed using
the internal algorithm of the 4000 Series Explorer™
Software (version 3.6; Applied Biosystems) with signal-
to-noise ratio (S/N) higher than 55 in MS mode and S/
N > 20 in MS/MS mode using cluster area optimization
feature. Up to 5 precursors from MS spectra with S/N >
100 were automatically selected for MS/MS fragmenta-
tion analysis using the interpretation method of the
Explorer™ Software. MS/MS acquisition of precursors
was controlled according to decreasing S/N value. The
isolation parameter for precursor selection was set to
200 as for the resolution of ion gating mechanism.
The mgf peak lists were generated from mass spectra
using the Peaks-to-Mascot function incorporated in the
Explorer™ software. From MS analysis, peaks in the m/
z range of 800-4000 and with S/N > 30 were included
in the mgf peak list. From MS/MS analysis, peaks fulfill-
ing two following criteria were included in the mgf peak
lists: (i) S/N > 15 and (ii) the m/z range between 68 and
the value of 50 m/z units lower than precursor’s m/z
value. The peak lists containing both MS and MS/MS
data were submitted through Mascot Daemon (ver.
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2.1.0) to Mascot Server (local installation of database
search engine, ver. 2.1.04). Parameters for combined
search (MS and MS/MS data) were as follows: database
- UniProt SwissProt (release 2011_01); taxonomy - all
entries; enzyme - trypsin; allowed missed cleavages - 1;
fixed modifications - carbamidomethyl (C); variable
modifications - oxidation (M), pyro-cmC (N-term
camC), pyro-glu (N-term E), pyro-glu (N- term Q); pep-
tide tolerance - 30 ppm; MS/MS tolerance - 250 mmu;
peptide charge - (+1); monoisotopic masses; instrument
- MALDI-TOF-PSD; no restrictions on protein molecu-
lar weight and pI value were applied. The hits passing
the following criteria were concluded as a successful
protein identification: (i) protein score C.I. = 100%, (ii)
total ion score C.I. = 100%, and (iii) and at least two
successfully fragmented peptides with ion score C.I =
100% each.
Determination of RBP4 level in plasma of patients from
LA-12 clinical evaluation
Patients with solid tumors undergoing Phase I clinical
trials were administered orally by LA-12. Blood was col-
lected into test-tubes containing 40 μL of 3.75%
K3EDTA before administration and 0.5-1-2-4-8 h after
administration, centrifuged at 4000 rpm at 4°C for 10
min. The plasma was transferred into labeled
Figure 1 Representative overview of peak 75 intensity (m/z = 22684, identified as rat RBP4 protein) in response to LA-12 dose and
time left after dosage (= sampling time). Peaks presented in each column correspond to the same LA-12 dose while peaks in a similar row
correspond to the same sampling time. The peak elevation with a maximum two hours after LA-12 dosage, responsively to LA-12 dose and in
overall correlation with Pt level, is a key observation in this study.
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polypropylene test-tubes and immediately frozen and
stored in a freezer (-18°C). Plasma samples from
patients containing 30 μg of total protein were separated
by SDS-PAGE and transferred onto nitrocellulose mem-
branes which were incubated with primary antibody
(Anti-RBP4, Sigma-Aldrich, USA, cat. No. HPA001641),
detected with peroxidase conjugated anti-rabbit IgG
(Dako, UK) and ECL detection reagents (GE Healthcare,
Sweden). Band intensities were quantified using Quanti-
tyOne 4.6.1 software (Bio-Rad, USA).
Results and discussion
Platinum concentrations (corresponding to LA-12 level)
were measured in plasma of rats administered four differ-
ent doses of LA-12 (37.5 - 75 - 150 - and 300 mg LA-12/
kg body weight). The measurements were conducted for
the samples collected at 0 - 2 - 8 - 24 - 48 - 72 h after
LA-12 dosage. As each sample was available in three
biological replicates (4 dosages × 6 times × 3 rats), 72
measurements of platinum concentration in rat plasma
were performed. Platinum concentration reached its
maximum 2 h after administration and then started to
decrease (see Additional file 1 for the statistically evalu-
ated results). In addition, ultrafiltrates of the plasma were
prepared from the samples collected at 0 - 2 - 8 h after
LA-12 dosage and Pt concentrations were measured with
maximum at 2 h (Additional file 1). The results serve as a
complementary set of Pt concentrations reflecting a free,
non-protein platinum content. In parallel, SELDI-TOF
MS proteomic profiles of the 72 plasma samples were
measured (each in two analytical replicates), 144 MS
spectra were thus obtained. Additional file 2 shows a
typical SELDI-TOF MS result. In total, 92 protein/pep-
tides were detected and quantified using Biomarker
Wizard software in each MS spectrum across the experi-
ment - see Additional file 3 for details of these 92 protein
and peptide clusters. Using Spearman correlation statisti-
cal analysis, we identified the protein/peptide peaks with
intensities that correlated with LA-12 dose and time
between the dosage and blood sampling. The values of
Spearman correlation for all detected peaks are presented
in Additional file 3. Only protein peak No. 75 (m/z =
22684) exhibited a statistically significant positive corre-
lation with platinum level in both rat plasma (Spearman
correlation coefficient 0.248) and plasma ultrafiltrate
(Spearman correlation coefficient 0.342). See Figure 1 for
its intensity in response to LA-12 dose and sampling
time. The experiment confirming that quantification
based on this peak was within the linear range of quanti-
fication is presented in Additional file 4. To reveal the
sequence identity of this protein peak, we used a three-
dimensional separation method followed by tandem mass
spectrometry (MALDI-MS/MS). In principle, plasma
proteins were first pre-separated on IMAC Spin columns
to obtain the same SELDI-TOF MS protein composition
as measured using analytical IMAC 30 chips. Second,
sample complexity was reduced by liquid chromatogra-
phy with reverse phase column (RP-LC). Individual RP-
LC fractions were then analyzed using SELDI-TOF MS
(normal phase NP-20 chip surface) to identify the frac-
tions containing proteins of interest. Only one fraction
(No. 11) contained the protein peak with m/z = 22684
(see Additional file 5 for confirmatory SELDI-TOF MS
spectra of all fractions in this m/z region). Third, fraction
No. 11 was then separated by tricine SDS-PAGE. The
corresponding protein band in the gel was identified
using protein profile matching and by comparison of
intact protein molecular weights as shown in Figure 2.
Sequence identity of this LA-12 positively correlating
protein was then obtained using MALDI-MS/MS as Reti-
nol-binding protein 4 (RBP4, UniProt accession No.
P04916, Mascot score 472, E-value 3.3 × 10-42, sequence
Figure 2 The process of identification of SELDI-TOF MS peak No.
75. After two-dimensional protein separation, the RP-LC fraction No.
11 containing protein corresponding with peak No. 75 was separated
on tricine SDS-PAGE. The corresponding gel band was identified by
comparison of molecular masses as well as by comparison of SELDI-
TOF MS spectrum with the electrophoregram. The band was then
excised from the gel, analyzed using mass spectrometry and identified
as RBP4 protein (UniProt accession No. P04916).
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coverage 55%, protein identification based on 9 tryptic
peptides and three of them were confirmed by MS/MS
analysis). See Figure 3 for corresponding for MALDI-MS
spectrum, Table 1 for overview of all identified peptides
and Additional file 6 for MS/MS spectra of identified
peptides.
RBP4 is a plasma protein characterized by Kanai and
Goodman [25] as a transport protein for retinol pro-
duced in hepatocytes to extrahepatic tissues. Retinoids
(retinol, all-trans retinoic acid and related signaling
molecules) are involved in cellular differentiation path-
ways and induce differentiation of various types of stem
cells [19]. Components of the retinol pathway are dis-
rupted in cancer, which suggests that a reduction of
retinoid signaling is involved in tumor development.
This applies to RBP4 and RBP1, amongst others, which
are down-regulated by methylation in cancer [26]. Also,
RBP4 is known to influence the differentiation of
adipocytes [27] and to mediate insulin resistance
through its functional relationship to glucose transporter
4 [28].
In principle, the RBP4 correlation with LA-12 observed
in our data might be caused by two major reasons: (i) by
formation of a RBP4/LA-12 complex analogous to that of
RBP4/retinol, or (ii) by induction of RBP4 protein expres-
sion. In order to explore the first hypothesis, we per-
formed a molecular modeling of the RBP4/LA-12 complex
to investigate whether LA-12 is able to bind non-cova-
lently into the retinol binding site in the RBP4 structure.
In such a case, RBP4 would hypothetically serve as a LA-
12 transport protein analogously to the retinol. The mod-
eling revealed that the central cavity of the protein is too
small for binding of LA-12 and the protein would have to
undertake a significant conformational change to form a
cavity capable of binding LA-12. The comparative analysis
of the apo and holo structures of RBP4 [29] revealed some
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Figure 3 MS spectrum of rat RBP4 protein (Plasma retinol-binding protein precursor (P04916, RET4_RAT). MALDI MS spectrum of tryptic
peptides extracted from excised and digested protein gel band (Figure 2) was measured in positive reflectron mode. Arrows indicate the
peptides identified in PMF analysis. Three peaks marked with “MS/MS” were successfully fragmented and identified with significant score (see
Additional file 5 for MS/MS peptide spectra).
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flexibility in the loop composed of residues 34-37 (Addi-
tional file 7). However, the other side of the binding cavity
is made of a rigid b-barrel, making significant enlargement
of the cavity unlikely. The above observations are sup-
ported by the fact that no peak with 553 Da mass shift
(corresponding to LA-12 molecular weight) was detected
in the surroundings of peak No. 75 in SELDI-TOF MS
spectra (Additional file 2). It is thus unlikely that a
hypothetical RBP4/LA-12 complex plays a significant role
in LA-12 and/or RBP4 function.
On the other hand, the second hypothesis of direct or
indirect induction of RBP4 expression by LA-12 is sup-
ported by induction of RBP4 by amantadine, a drug bear-
ing an adamantine group closely related to that present
in LA-12 [30]. Additional indirect evidence was indicated
by Hung et al. who reported increased level of urinary
RBP4 in mice after cisplatin treatment [31]. This suggests
similar mechanisms for RBP4 induction by both LA-12
and cisplatin. The time dependence of the RBP4 level in
rat plasma also corresponds well with the protein stability
which has been estimated for approximately 30 h [32].
To independently verify that the identified peak in the
rat experimental system is indeed RBP4 and to investi-
gate RBP4 induction by LA-12 in humans, we analyzed
plasma samples using western blotting with an RBP4
specific antibody. Although this antibody to human
RBP4 was not effective in rat samples, we demonstrated
that circulating RBP4 levels correlated well with plati-
num levels in human plasma of 12 randomly selected
patients involved in Phase I clinical trials of LA-12 (see
Figure 4 and Additional file 8).
Functionally, RBP4 is aberrantly expressed in a number
of human cancers, with promoter hypermethylation lead-
ing to down-regulation of expression in esophageal squa-
mous cancer [26]. Most recently, Lorkova et al. [33]
Table 1 Rat RBP4 protein identification data
Plasma retinol-binding protein precursor (RBP4)
UniProt Accession:
P04916 (RET4_RAT)
Protein Score 472
Protein Score C.I. % 100
Total Ion Score 394
Total Ion Score C.I. % 100
Sequence Coverage % 55
E-value 3.3 × 10-42
Obsrv. Mass Calc. Mass ± Da Start Seq. End Seq. Miss Cleav. Ion Score C.I. % E-value Peptide Sequence+Modification
1155.6251 1154.6124 0.0054 38 47 0 — — — R.FSGLWYAIAK.K
1226.6394 1225.6243 0.0078 108 117 0 — — — K.YWGVASFLQR.G
1343.6510 1342.6299 0.0138 172 181 1 — — — R.QRQEELCLER.Q + Pyro-glu (N-term Q)
1360.6714 1359.6565 0.0077 172 181 1 27 39 0.85 R.QRQEELCLER.Q
2079.9431 2078.9367 -0.0009 140 157 0 148 100 2.9e-13 R.LQNLDGTCADSYSFVFSR.D
2129.0942 2128.1138 -0.0269 1 20 0 — — — -.MEWVWALVLLAALGGGSAER.D
2279.1006 2278.1004 -0.0071 49 68 0 — — — K.DPEGLFLQDNIIAEFSVDEK.G
2407.1960 2406.1954 -0.0067 48 68 1 132 100 2.1e-11 K.KDPEGLFLQDNIIAEFSVDEK.G
2705.1455 2704.1500 -0.0118 118 139 0 87 100 8.6e-8 R.GNDDHWIIDTDYDTFALQYSCR.L
Table includes protein name, UniProt accession number and entry name, Protein Score, Protein Score C.I. %, Total Ion Score, Total Ion Score C.I. %, Sequence
Coverage %, E-value; list of peptides matched to the identified protein with their observed and calculated m/z values, error of the measurement (Da), start and
end position in protein sequence, number of missed cleavages, Ion Score, C.I. % for peptides confirmed by MS/MS, their E-value, sequences of identified peptides
and note about their modification. The data correspond to gel piece excised from the gel as shown in Figure 2, no other protein was identified with significant
score in tryptic digest of this gel band.
Figure 4 Similar trends in average platinum concentration and
RBP4 level (measured as average integral optical density by
western blotting with immunochemical detection) in response
to sampling time in patients’plasma. Data from individual
patients are presented in Additional file 8.
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reported a decreased level of RBP4 in sera of ovarian can-
cer patients using two-dimensional gel electrophoresis
and confirmed this observation via western blotting and
ELISA. In view of the roles of retinol in cellular differen-
tiation, the lack of RBP4 expression is thought to be
involved in maintaining the undifferentiated nature of
cancer cells [19]. Thus, in addition to acting as a marker,
elevated RBP4 levels following treatment with LA-12
may have functional importance through the restoration
of retinol-induced signaling pathways in cancer cells. As
such, these data open very interesting, much more com-
plex and not yet investigated hypothesis on RBP4 invol-
vement in cancer development and the mechanisms of
action of LA-12 and similar anti-cancer drugs.
Conclusions
Using mass spectrometry-based proteomics, we identi-
fied induction of RBP4 by the new anticancer agent LA-
12 in both rat and human plasma. RBP4 is a plasma
protein involved in the transport of retinol, which serves
as a differentiation-inducing molecule in various stem
cells and is aberrantly expressed in cancer.
Additional material
Additional file 1: Concentration profiles of platinum in rat plasma
and plasma ultrafiltrate in response to LA-12 dose and to time after
LA-12 dosage (Kruskal-Wallis ANOVA). The platinum concentrations
(corresponding to LA-12 level) measured in the plasma samples of the
rats dosed with four different LA-12 doses
Additional file 2: The typical SELDI-TOF MS spectrum of plasma
from rats dosed with LA-12. The spectra in m/z range 2000-80000 (A),
2000-30000 (B) and 20500-25600 (C) are shown. The arrows indicate the
position of peak cluster No. 75 (m/z = 22684) identified as RBP4 protein.
Additional file 3: Overview of peptide and protein clusters and
their correlation coefficients with platinum level in rat plasma and
plasma ultrafiltrate. Overview of peptide and protein clusters and their
correlation coefficients with platinum level in rat plasma and plasma
ultrafiltrate.
Additional file 4: Quantification of m/z = 22684 peak in primary
proteomic study lies within linear range of quantification. An
independent experiment using beta-lactoglobulin A protein standard
was performed to confirm that RBP4 quantification using SELDI-TOF MS
lies within linear range of quantification.
Additional file 5: Overview of protein fractions obtained by reverse-
phase protein fractionation as measured by SELDI-TOF MS (NP-20
surface). Overview of protein fractions obtained by reverse-phase
protein fractionation as measured by SELDI-TOF MS (NP-20 surface).
Protein with m/z = 22684 was detected in fraction 11 only and
confirmed in a mixture of fractions 11,12,13 and 14.
Additional file 6: MS/MS spectra of rat RBP4 identified peptides.
Figure A. MS/MS spectrum of peptide m/z = 2079.943. Peptide was
selected from MS spectrum of Plasma retinol-binding protein Precursor
P04916 (see Figure 3 in the main text). Measured fragment series y and
b are marked in spectrum and their m/z values are listed in table
together with amino acid sequence of peptide. Asterisk indicates
carbamidomethylation of cysteine residue. Figure B. MS/MS spectrum of
peptide m/z = 2407.196. Peptide was selected from MS spectrum of
Plasma retinol-binding protein precursor P04916 (see Figure 3 in the
main text). Measured fragment series y and b are marked in spectrum
and their m/z values are listed in table together with amino acid
sequence of peptide. Figure C. MS/MS spectrum of peptide m/z =
2705.146. Peptide was selected from MS spectrum of Plasma retinol-
binding protein precursor P04916 (see Figure 3 in the main text).
Measured fragment series y and b are marked in spectrum and their m/z
values are listed in table together with amino acid sequence of peptide.
Asterisk indicates carbamidomethylation of cysteine residue.
Additional file 7: The structural alignment of the ribbon models of
the apo structure of human plasma retinol-binding protein (PDB ID
1BRT) and its holo structure (PDB ID 1BRP) in the complex with the
native ligand retinol. The apo structure is shown in magenta, the holo
structure is in blue and the retinol is colored by atom type. The most
significant difference between two forms of the protein is due to the
conformational change involving residues from 34 to 37 (black arrow).
The figure was prepared using the software PyMol v0.99 (DeLano
Scientific LCC, South San Francisco, CA, USA).
Additional file 8: The correlation between platinum and RBP4
protein levels in plasma from 12 patients undergoing the Phase I
clinical trials. Each patient is represented by one chart (A-L). Left axis
and triangles corresponds with platinum level while right axis and
squares stand for RBP4 level. Original western blotting data are
presented above each chart.
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